RxDoctor Payments Data

Zachary Hale, MD

Clinical Cardiac Electrophysiology · Asheville, NCNPI 1770929655

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (42.0%), grants and travel and lodging — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Medtronic at 37.3% of the total.

$55,799in general payments, 2019–2025

Across 644 payments — averaging $86.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$21K
  • Boston Scientific$15K
  • Abbott$8K
  • Biosense Webster, Inc.$3K
  • Biotronik Inc.$2K
  • Medical Device Business Services, Inc.$1K
  • plus $5K from 24 others

What the payments were for

  • Speaking & faculty fees$4,9009%
  • Grants$16,00029%
  • Travel & lodging$11,14220%
  • Food & beverage$23,45442%
  • Education$3041%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$55,799 in reported general payments places this provider in the 75th percentile of 98 clinical cardiac electrophysiology providers in North Carolina.

See all clinical cardiac electrophysiology providers in North Carolina

Medicare billing

Part B allowed, 2024
$390,689
Medicare patients
767
Services billed
4,512

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban321$296,976
EntrestoSacubitril/Valsartan56$44,961
XareltoRivaroxaban36$37,450
JardianceEmpagliflozin31$29,897
MultaqDronedarone Hcl16$21,936
Dofetilide54$7,191
Metoprolol Succinate308$3,541
Flecainide Acetate112$3,063
Amiodarone Hcl49$1,184
Losartan Potassium108$1,069
SotalolSotalol Hcl28$791
Diltiazem 24hr Er (Cd)Diltiazem Hcl29$558
Mupirocin64$464
Potassium Chloride34$428
Carvedilol59$355

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$868$296,976321 claims
NovartisEntresto$276$44,96156 claims
Johnson & JohnsonXarelto$79$37,45036 claims
Boehringer IngelheimJardiance$591$29,89731 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 98 clinical cardiac electrophysiology providers in North Carolina.

Other clinical cardiac electrophysiology in Asheville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →